Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 632-639

  Usher, Cara ^a   Tilson, Lesley ^a   Bennett, Kathleen ^a   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Community drugs schemes; Cost containment; Pharmaceutical expenditure; Time series

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG COST; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; IRELAND; MEDICAL SERVICE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRESCRIPTION;

COST CONTROL; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; HEALTH EXPENDITURES; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH, REIMBURSEMENT; IRELAND; PRESCRIPTION DRUGS; STATE MEDICINE;

EID: 84858589606     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.025     Document Type: Article

References (16)

1. Welcome to the HSE primary care reimbursement service Health Service Executive, Accessed January 10, 2012. http://www.pcrs.ie.
2. Corporate pharmaceutical unit. 2006 IPHA agreement Health Service Executive, Ireland, Accessed February 10, 2012. http://www.hse.ie/eng/about/Who/cpu/agreements.html.
3. Corporate pharmaceutical unit. 2006 APMI agreement Health Service Executive, Ireland, Accessed 10 February 2012. http://www.hse.ie/eng/about/Who/cpu/agreements.html.
4. Corporate pharmaceutical unit. Appendix to 2006 IPHA agreement Health Service Executive, Ireland, Accessed February 10, 2012. http://www.hse.ie/eng/about/Who/cpu/agreements.html.
5. Corporate pharmaceutical unit. Appendix to 2006 APMI agreement Health Service Executive, Ireland, Accessed February 10, 2012. http://www.hse.ie/eng/about/Who/cpu/agreements.html.
6. Wagner A.K., Soumerai S.B., Zhang F., et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27:299-309.
7. Lu C.Y., Law M.R., Soumerai S.B., et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther 2011, 33:135-144.
8. Bennett K., Barry M., Tilson L. Pharmaceuticals. Projecting the Impact of Demographic Change on the Demand for and Supply of Healthcare in Ireland 2009, Economic and Social Research Institute, Dublin, Ireland, Research Series 13, Accessed March 2011. http://www.esri.ie/UserFiles/publications/20091023164031/RS013.pdf, R. Layte (Ed.).
9. Moreno-Torres I., Puig-Junoy J., Raya J.M. The impact of repeated cost-containment policies on pharmaceutical expenditure: experience in Spain. Eur J Health Econ 2011, 12:563-573.
10. Generic drug utilisation in Ireland in 2008 National Centre for Pharmacoeconomics, Accessed August 10, 2011. http://www.ncpe.ie/u_docs/doc_163.pdf.
11. Godman B., Bucsics A., Burkhardt T., et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Exp Rev Pharmacoecon Outcomes Res 2008, 8:357-371.
12. McGinn D., Godman B., Lonsdale J., et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Exp Rev Pharmacoecon Outcomes Res 2010, 10:73-85.
13. Coma A., Zara C., Godman B., et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Exp Rev Pharmacoecon Outcomes Res 2009, 9:569-581.
14. Walshe V., Nash A., Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006, 99:144-145.
15. Towse A. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?. Health Aff 2003, 22:42-45.
16. Anell A. Priority setting for pharmaceuticals. Eur J Health Econ 2004, 5:28-35.